AOP Orphan Pharmaceuticals AG (AOP Orphan) took over the Viennese pharmaceutical company Amomed and the Luxembourgish health-tech company SciPharm in September 2020. All existing jobs have been kept and form the basis for a growth strategy which should also create further jobs in the coming years. New chances and opportunities will also open for Austria as a hub for research and business. In addition, the company assumes that there will be a significant increase in revenues and that new markets will be tapped in the period until 2030. The entire global market is currently served from Vienna.
In the third quarter of 2020, AOP Orphan took over the health care companies Amomed Pharma GmbH and SciPharm S.à.r.l.
AOP Orphan thus continues its consistent growth trajectory towards being a pan-European health care group with a focus on rare and complex diseases.
Researching, developing, and marketing new products and services are geared towards the entire global market, which is already covered from Canada through to South America and Australia!
The takeover will mean that the AOP Orphan Group’s team will grow from 220 to approx. 350 employees.
“From the beginning, it was our priority to preserve all existing jobs and we have done just that. By developing innovative therapies and a broader territorial presence, we are convinced that we will continue to generate significant growth!”
The Group intends to increase its revenues to one billion euros by 2030.
“Due to the strategic focus on providing holistic therapy solutions which include drugs, medical devices and patient services and an innovative product pipeline, we are convinced that this positive development will come to fruition,” Steiner continues.
FLTR: Dr Rudolf Widmann, CHIEF THERAPEUTICS DEVELOPMENT OFFICER, BOARD MEMBER, FOUNDER and Andreas Steiner, CEO, CHAIRMAN OF THE BOARD
AOP currently has various products for around 10 indications in the pipeline, including for septic shock, Huntington's chorea (a functional disorder of the brain characterized by motor and behavioral problems) or chronic myeloid leukemia, a malignant disease of the bone marrow.
As well as developing innovative therapies, the international team also works on medical devices and software solutions, e.g. for patients with pulmonary arterial hypertension (PAH). Patients are connected to the doctors treating them by an app which enables the dose of the drug which is administered using a pump to be controlled - precisely and tailored to the individual patient.
The AOP Orphan Group manufactures 80 percent of its drugs in Europe - an aspect which has become more and more relevant since the start of the COVID-19 pandemic. The AOP Orphan Group now has more than 20 subsidiaries and representative offices across the whole of Europe as well as in the United Arab Emirates and Israel.
We aim to enhance this presence and tap into new markets!
The AOP Orphan Group is the European pioneer in the field of special diseases with a complex management. After the takeover, the health care group will concentrate on four therapeutic divisions: hemato-oncology, cardiology & pulmonology, neurology & metabolic disorders, and intensive care medicine. The company focuses on developing holistic therapy solutions that place patients at the heart of the matter.
The foundation of the AOP Orphan subsidiary OrphaCare GmbH in 2018, with its focus on developing patient services, cemented this patient-centric approach.
The takeover of Amomed and SciPharm brings the research and development of drugs as well as the development of medical devices and patient services together under one roof, creating optimal conditions for developing integrated therapies.
OrphaCare’s hotline, for example, is a key service in the everyday life of people suffering with PAH. The hotline does not just provide technical support: it is also manned by experts around the clock.
“We as doctors very much appreciate this approach, as do the patients. Because it is important to ensure long-term treatment with a life-saving drug. This expert hotline is of great value and is now indispensable in providing care to patients.”
AOP Orphan Pharmaceuticals AG
Wilhelminenstraße 91/IIf, 1160 Vienna
Ms. Nina Roth, MAS
T: +43 676 3131509
© AOP Orphan/© VERDINO | Angelika Schiemer
PC 1: Mr. Andreas Steiner, CEO, AOP Orphan
PC 3: Univ. Prof. Irene Lang, MD
© AOP Orphan/Natascha Unkart & Isabelle Köhler
PC 2: Dr. Rudolf Widmann and Mr. Andreas Steiner with the Merkur Award: AOP Orphan was awarded the innovation prize for “Life Sciences” in autumn 2018.